For the year ending 2025-12-31, EBS has $1,318,600K in assets. $796,000K in debts. $205,400K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 205,400 | |||
| Restricted cash | 3,700 | |||
| Accounts receivable, net | 84,200 | |||
| Inventories, net | 343,400 | |||
| Prepaid expenses and other current assets | 25,800 | |||
| Total current assets | 662,500 | |||
| Property, plant and equipment, net | 205,400 | |||
| Intangible assets, net | 436,500 | |||
| Other assets | 14,200 | |||
| Total assets | 1,318,600 | |||
| Accounts payable | 55,600 | |||
| Accrued expenses | 12,200 | |||
| Accrued compensation | 41,800 | |||
| Current tax liability | 6,800 | |||
| Other current liabilities | 15,800 | |||
| Total current liabilities | 132,200 | |||
| Debt | 572,100 | |||
| Deferred tax liability | 37,800 | |||
| Other liabilities | 53,900 | |||
| Total liabilities | 796,000 | |||
| Common stock, 0.001 par value per share 200.0 shares authorized, 60.9 and 59.9 shares issued 52.1 and 54.3 shares outstanding, respectively | 100 | |||
| Treasury stock, at cost, 8.7 and 5.6 common shares, respectively | 252,600 | |||
| Additional paid-in capital | 942,400 | |||
| Accumulated other comprehensive loss, net | -7,500 | |||
| Accumulated deficit | -159,800 | |||
| Total stockholders equity | 522,600 | |||
| Total liabilities and stockholders equity | 1,318,600 | |||
Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS)